549835
2,4,6-三(二甲氨基)均三嗪
96%
别名:
六甲三聚氰胺, 六甲蜜胺
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C9H18N6
化学文摘社编号:
分子量:
210.28
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12352100
EC Number:
211-428-4
MDL number:
产品名称
2,4,6-三(二甲氨基)均三嗪, 96%
InChI key
UUVWYPNAQBNQJQ-UHFFFAOYSA-N
InChI
1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3
SMILES string
CN(C)c1nc(nc(n1)N(C)C)N(C)C
assay
96%
mp
171-175 °C (lit.)
functional group
amine
Quality Level
正在寻找类似产品? 访问 产品对比指南
General description
2,4,6-Tris(dimethylamino)-1,3,5-triazine exhibits antitumor activity.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Triazines and related products. Part 26. Synthesis and chemistry of bicyclic analogues of the antitumour drug 2, 4, 6-tris (dimethylamino)-1, 3, 5-triazine (hexamethylmelamine).
Langdon SP, et al.
Journal of the Chemical Society. Perkin Transactions 1, 993-998 (1984)
John K Chan et al.
Gynecologic oncology, 92(1), 368-371 (2004-01-31)
Altretamine has reported efficacy in the treatment of recurrent ovarian cancer following platinum-based therapy. This report presents the cases of two long-term survivors with recurrent ovarian cancer given oral altretamine. Two patients diagnosed with stage IIIC ovarian cancer underwent optimal
Michael J Kelner et al.
Cancer chemotherapy and pharmacology, 63(1), 19-26 (2008-02-29)
Irofulven (MGI 114, NSC 683863) is a semisynthetic derivative of illudin S, a natural product present in the Omphalotus illudins (Jack O'Lantern) mushroom. This novel agent produces DNA damage, that in contrast to other agents, is predominately ignored by the
P Sørensen et al.
Gynecologic oncology, 81(1), 58-62 (2001-03-30)
The purpose of this phase II study was to evaluate on an intent-to-treat basis the activity and toxicity of single-agent vinorelbine (VRL) as second-line chemotherapy of patients with platinum-resistant ovarian cancer. Platinum-resistant disease was defined as disease refractory to or
M L Rothenberg et al.
Gynecologic oncology, 82(2), 317-322 (2001-09-05)
The aim of this study was to evaluate the 2-year survival rate in a group of women in complete clinical remission (cCR) from Stage III ovarian cancer following front-line therapy who were then treated with a 6-month course of altretamine.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持